Safety and response rates with Abecma (idecabtagene vicleucel) were seen to vary with race in people with relapsed or refractory multiple myeloma (RRMM), but…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
A committee of the European Medicines Agency (EMA) has recommended that Elrexfio (elranatamab) — a therapy already in use in the U.S. — be…
While diabetes is more frequent among Black people than white people, it’s associated with poorer survival outcomes in white people with multiple myeloma, a…
People with hard-to-treat multiple myeloma given a regimen of Venclexta (venetoclax) plus dexamethasone lived longer than those treated with Pomalyst (pomalidomide) plus the…
A cell-based vaccine designed to promote immune responses against survivin, a protein that helps tumor cells survive and expand, was found to be safe and…
The Gabrail Cancer Center (GCC) in Canton, Ohio is the first site to open in a Phase 1b clinical trial that’s evaluating STAR-LLD, Starton…
